9.7 هپاتیت C: تظاهرات کلینیکی
SD1000: High Sustained Viral Response Rate in 1380 patients with hepatitis C using a fixed-dose combination tablet of sofosbuvir and daclatasvir (Sovodak) - a multicenter phase 3 clinical trial
Shahin Merat,Hossein Poustchi,Amir-Houshang Sharifi,Eskandar Hajiani,Abdolsamad Gharavi,Jalal Karimi,Fariborz Mansour-Ghanaei,Mohammad-Reza Fattahi,Mohammad-Hossein Somi,Mohammad-Reza Ghadir,Hamid Kalantari,Farshad Sheikhesmaeili,Nadieh Baniasadi,Seyedhamid Moosavy,Masoudreza Sohrabi,Masood Ziaee,Mohammad Javad Zahedi,Behrooz Afshar,Marjan Mokhtare,Shahnaz Sali,Babak Sayad,Abazar Parsi,Alireza Bakhshipour,Afsaneh Sharifian,Taghi Amiriani,Azita Ganji,Fereidoun Rahmani Samani,Mohammad Ghezlou,Raika Jamali,Masoomeh Sofian,Ladan Goshayeshi,Amir Ali Sohrabpour,Seyed Mohammad Valizadeh Toosi,Layli Eslami,Ahmad Hormati,Iradj Maleki,Alireza Norouzi,Ali Akbar Shayesteh,Zahra Abna,Hafez Fakheri,Alireza Jahanbakhsh,Adel Fallah Ghajary,Mohammad Minakari,Hossein Sardarian,Mojtaba Fattahi Abdizadeh,Fatemeh Roozbeh,Shahram Agah,Alireza Nateghi,Babak Fattahi,Reza Malekzadeh